1. London MJ, et al. Perioperative [beta]-Adrenergic Receptor Blockade: Physiologic Foundations and Clinical Controversies. Anesthesiology 2004; 100: 170–175.
2. Stevens RD, Burri H, Tramer M. Pharmacologic Myocardial Protection in Patients Undergoing Noncardiac Surgery: A Quantitative Systematic Review. Anesth Analg 2003; 97: 623–633.
3. Bangalore S, et al. Cardiovascular Protection Using Beta-Blockers. A Critical Review of the Evidence. J Am Coll Cardiol 2007; 50: 159–241.
4. Škarvan K. Perioperační betablokáda. Anest intensiv Med 2007; 18: 286–295.
5. Horáček M. Mají betablokátory stále ještě místo v ochraně myokardu? Anest intensiv Med 2007; 18: 296–300.
6. POISE Study Group: Effects of extended-release metoprolol succinate in patientsundergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839–1847.
7. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade. A Report of the American College of Cardiology Foundation/Američan Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2102–2128.
8. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Risk Management in Non-cardiac Surgery of European Society of Cardiology and endorsed by European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 92–137.
9. Davis E, Loiacono R, Summers RJ. The rush to adrenaline: drugs in sport acting on the beta-adrenergic system. Br J Pharmacol 2008; 154: 584–597.
10. Eliasch H, Rosén A, Scott HM. Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J 1967; 29: 671–683.
11. Taggart P, Carruthers M, Somerville W. Electrocardiogram, plasma catecholamines and lipids, and their modification by oxprenolol when speaking before an audience. Lancet 1973; 302: 341–346.
12. Taggart P, Carruthers M. Supression by oxprenolol of adrenergic respones to stress. Lancet 1972; 300: 256–258.
13. Webster NR, Galley HF. Immunomodulation in the critically ill. Brit J Anaesth 2009; 103: 70–81.
14. Träger K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003; 9: 271–278.
15. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: Propranolol. Crit Care Med 2007; 35(Suppl.): S616–S620.
16. Berk JL, et al. The Treatment of Endotoxin Shock by Beta Adrenergic Blockade. Ann Surg 1969; 169: 74–81.
17. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970; 130: 1025–1034.
18. Berk JL, et al. The treatment of shock with beta adrenergic blockade. Arch Surg 1972; 104: 46–51.
19. Perreira C, et al. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005; 37: 1948–1961.
20. Herndon DN, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J. Med 2001; 345: 1223–1229.
21. Barrow RE, et al. The Use of Beta-Adrenergic Blockade in Preventing Trauma-Induced Hepatomegaly. Ann Surg 2006; 243: 115–120.
22. Werdan K, et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 2009; 87: 266–274.
23. Leibovici L, et al. Relative tachycardia in patients with sepsis: an independent risk factor for mortality. Q J Med 2007; 100: 629–634.
24. Gutierrez J, et al. Effect of beta blockers on sepsis outcome. Med Sci Monit 2009; 15: 499–503.
25. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006; 139: 686–694.
26. Suzuki T, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005; 33: 2294–2301.
27. Schmidt H. et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med 2008; 36: 967–970.
28. Schmittinger CA, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008; 12: R99.
29. Friese RS, et al. Could Beta Blockade Improve Outcome After Injury by Modulating Inflammatory Profiles? J Trauma 2008; 64: 1061–1068.
30. Cotton BA, et al. Beta-Blocker Exposure is Associated With Improved Survival After Severe Traumatic Brain Injury. J Trauma 2007; 62: 26–35.
31. Arbabi S, et al. Beta-Blocker Use is Associated With Improved Outcomes in Adult Trauma Patients. J Trauma 2007; 62: 56–62.